Most Read Articles
5 days ago
Among patients with rheumatoid arthritis, those who are obese are more likely to have worse disease activity, lower functional ability and poorer health-related quality of life compared with their nonobese counterparts, a study has found.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
17 May 2017
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.

Smoking cessation improves survival in diabetics

11 Apr 2018

Quitting smoking following diabetes diagnosis appears to significantly cut mortality risk, particularly when paired with proper weight management, a recent Korea study has shown.

Researchers recruited 17,204 males (median age 52 years) who were newly diagnosed with type 2 diabetes and free from stroke or myocardial infarction. Survival regression analysis was performed to determine the risk of all-cause and cardiovascular diseases.

Multivariate adjusted analysis showed that men who quit smoking but showed no changes in body mass index (BMI) had a significantly lower risk of all-cause mortality compared with sustained smokers (adjusted hazard ratio [HR], 0.68; 95 percent CI, 0.46–1.00; p=0.05).

Men who quit smoking but gained BMI also showed a reduced risk of all-cause mortality, but the effect was not statistically significant (adjusted HR, 0.67; 0.36–1.24; p=0.21). Interestingly, smoking cessation coupled with BMI loss resulted in a significant increase in the risk of mortality (adjusted HR, 1.76; 1.13–2.73; p=0.01).

None of the patient groups were associated with significant changes in the risk of cardiovascular diseases. However, smoking cessation with BMI loss was associated with a nominal increase in the risk (adjusted HR, 1.09; 0.71–1.68; p=0.71), while cessation with BMI gain led to a marginal drop in the risk (adjusted HR, 0.94; 0.60–1.47; p=0.79).

The findings of the present study suggest that physicians should inform newly-diagnosed type 2 diabetes patients about the potential survival benefits of smoking cessation, as well weight management strategies that may help maximize the said benefits, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Among patients with rheumatoid arthritis, those who are obese are more likely to have worse disease activity, lower functional ability and poorer health-related quality of life compared with their nonobese counterparts, a study has found.
30 May 2016
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
17 May 2017
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.